Almost half of patients who are initial responders to nabiximols oromucosal spray (Sativex) for spasticity in MS have discontinued the medicinal cannabis at 18 months, a European study shows. An Italian study of 1845 MS patients prescribed the treatment for moderate to severe spasticity resistant to other medications confirmed most patients (81.4%) had the requisite ...
Half of MS patients discontinue medicinal cannabis
By Mardi Chapman
17 Jul 2020